Atriva Therapeutics GmbH
Atriva Therapeutics is a biopharmaceutical company developing first-in-class host-cell-targeting antiviral and immunomodulatory therapies for viral diseases such as influenza and SARS-CoV-2.
Classification
Profile
Funding
Funding details not yet available.
First-in-class host-cell-targeting antiviral and immunomodulatory therapies for severe influenza and dangerous viral infections with broad-spectrum activity.
Patients suffering from severe influenza, SARS-CoV-2, and other dangerous viral infections, alongside regulatory bodies requiring safe treatments.
- Product Sales (Future) - Once approved, oral Zapnometinib sold to hospitals, pharmacies, and government stockpiles
Clinical Development & Regulatory Pathways - Phase IIa (COVID-19) and upcoming Phase IIb/III (influenza) generate data that act as a channel · Scientific Conferences & Publications - ESWI, Lancet Discovery Science, etc., raise awareness among clinicians and partners · Direct Business-to-Business (B2B) Outreach - Meetings with pharma partners, gover
Entered an exclusive letter agreement with Canadian Biocure Technologies, Inc. for a reverse takeover transaction, indicating a strategic corporate alliance.
Non-clinical research activities, including cell line and animal studies, and planning for Phase 1 clinical trials.
Team of leading scientists in viral disease research, proprietary intracellular Raf/MEK/ERK signaling pathway targeting technology, and lead candidate zapnometinib.
Developing host-cell-targeting therapies, conducting non-clinical studies for influenza and SARS-CoV-2, and advancing drug candidates like ATR-002.
Scientific Credibility & Thought-Leadership - Publishing peer-reviewed data, presenting at conferences, and maintaining transparent trial re · Strategic Partnerships & Licensing - Co-development agreements, potential out-licensing of Zapnometinib to larger pharma for global commerci · Regulatory & Reimbursement Engagement - Early dialogue with EMA,
Competes in the antiviral market with first-in-class host-cell-targeting approach, differentiating via broad-spectrum activity against RNA viruses and immunomodulatory effects.
High unmet medical need for treatments against severe influenza and dangerous viral infections like SARS-CoV-2.
- Accelerate Licensing Strategy
- Map out a 12-month licensing pipeline - target 3 potential partners, assign a senior BD lead, and set quarterly milestones (MOU, term she
- Value Proposition ↔ Customer Segments - The broader the antiviral spectrum, the larger the addressable market (hospital systems, governme
- Clinical Validation - Phase I safety data and Phase IIa RESPIRE results published in eClinicalMedicine provide credible scientific back
No investors recorded yet.